Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.

Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM.

Diabetes Care. 2007 Jul;30(7):1689-93. Epub 2007 Apr 17.

PMID:
17440170
2.

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Johnson JA, Majumdar SR, Simpson SH, Toth EL.

Diabetes Care. 2002 Dec;25(12):2244-8.

PMID:
12453968
3.
4.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
5.

Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.

Aquilante CL, Zhang W, McCollum M.

Curr Med Res Opin. 2007 Mar;23(3):489-94.

PMID:
17355730
6.
7.

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.

PMID:
17245800
8.

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.

PMID:
16186261
9.

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

Pharmacotherapy. 2005 Jun;25(6):810-6.

PMID:
15927899
10.

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.

Gulliford M, Latinovic R.

Diabetes Metab Res Rev. 2004 May-Jun;20(3):239-45.

PMID:
15133756
11.

Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.

Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, Radican L.

Curr Med Res Opin. 2010 Jul;26(7):1697-703. doi: 10.1185/03007995.2010.489029.

PMID:
20465367
13.
14.
15.
16.

Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.

Rascati K, Richards K, Lopez D, Cheng LI, Wilson J.

Diabetes Obes Metab. 2013 Oct;15(10):901-5. doi: 10.1111/dom.12103. Epub 2013 Apr 18.

PMID:
23531154
17.

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.

Johnson JA, Simpson SH, Toth EL, Majumdar SR.

Diabet Med. 2005 Apr;22(4):497-502.

PMID:
15787679
18.

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

Evans JM, Ogston SA, Emslie-Smith A, Morris AD.

Diabetologia. 2006 May;49(5):930-6. Epub 2006 Mar 9.

PMID:
16525843
19.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
20.

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

Bowker SL, Yasui Y, Veugelers P, Johnson JA.

Diabetologia. 2010 Aug;53(8):1631-7. doi: 10.1007/s00125-010-1750-8. Epub 2010 Apr 21.

PMID:
20407744

Supplemental Content

Support Center